- ISIN
- CA14161Y2006
- Sector
- Healthcare
- IPO Date
- Jan 15, 2019
Highlights
- Market Cap
- $112.29M
- Enterprise Value
- $91.00M
- EPS (TTM)
- -$0.38
- Gross Profit (TTM)
- -$25.95K
- EBITDA (TTM)
- -$34.00M
- Year Range
- $0.88 - $1.71
- Target Price
- $8.00
- ROA (TTM)
- -143.18%
- ROE (TTM)
- -189.17%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CRDL Performance Chart
Cardiol Therapeutics Inc Class A (CRDL) is up 17.4% since the beginning of the year. At $1 per share, CRDL is trading 34.5% below its 52-week high of $2. Investors who bought $1,000 worth of CRDL shares 5 years ago would now be looking at an investment worth $412.
Loading charts...
Returns By Period
Cardiol Therapeutics Inc Class A (CRDL) has returned 17.43% so far this year and -14.50% over the past 12 months.
Cardiol Therapeutics Inc Class A
- 1D
- -2.61%
- 1M
- -15.79%
- YTD
- 17.43%
- 6M
- 18.62%
- 1Y
- -14.50%
- 3Y*
- 18.79%
- 5Y*
- -16.24%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
CRDL Monthly Returns History
Based on dividend-adjusted daily data since Jan 15, 2019, CRDL's average daily return is +0.08%, while the average monthly return is +0.59%. At this rate, an investment would double in approximately 9.8 years.
Historically, 44% of months were positive and 56% were negative. The best month was Feb 2024 with a return of +68.9%, while the worst month was Nov 2021 at -44.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.
On a daily basis, CRDL closed higher 45% of trading days. The best single day was Feb 15, 2024 with a return of +42.3%, while the worst single day was Nov 3, 2021 at -25.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.33% | 7.29% | 32.35% | 2.22% | -11.59% | -8.20% | 17.43% | ||||||
| 2025 | 10.16% | -18.44% | -15.67% | 13.43% | 13.64% | 8.80% | 9.56% | -27.52% | -0.93% | 5.61% | -7.08% | -9.16% | -25.48% |
| 2024 | 44.69% | 68.85% | -12.14% | 11.05% | 30.35% | -22.90% | 6.93% | -10.19% | 2.06% | -9.09% | -10.00% | -20.99% | 51.80% |
| 2023 | 38.10% | -24.69% | -8.13% | 27.15% | 8.80% | 32.03% | 21.35% | 1.85% | -18.64% | -7.26% | 10.42% | -8.00% | 65.33% |
| 2022 | -0.00% | -9.19% | -8.93% | -10.46% | -2.19% | -1.49% | 0.00% | -15.15% | -8.04% | -41.86% | -13.94% | -1.03% | -72.43% |
| 2021 | 12.84% | 41.87% | 0.29% | -1.43% | -21.16% | -11.76% | -6.25% | 66.22% | 10.96% | -12.77% | -44.75% | -7.50% | -15.14% |
Benchmark Metrics
Cardiol Therapeutics Inc Class A has an annualized alpha of 1.37%, beta of 1.18, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since January 16, 2019.
- This stock participated in 169.41% of S&P 500 Index downside but only 60.38% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 1.37%
- Beta
- 1.18
- R²
- 0.07
- Upside Capture
- 60.38%
- Downside Capture
- 169.41%
Return for Risk
Risk / Return Rank
CRDL ranks 33 for risk / return — below 33% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Cardiol Therapeutics Inc Class A (CRDL) and compare them to S&P 500 Index.
| CRDL | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.45 | ||
| Sortino ratioReturn per unit of downside risk | -2.88 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.41 | -0.38 |
| Calmar ratioReturn relative to maximum drawdown | -0.37 | 2.93 | -3.29 |
| Martin ratioReturn relative to average drawdown | -0.54 | 13.52 | -14.06 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cardiol Therapeutics Inc Class A. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cardiol Therapeutics Inc Class A was 92.71%, occurring on Apr 5, 2023. The portfolio has not yet recovered.
The current Cardiol Therapeutics Inc Class A drawdown is 81.91%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -92.71%Apr 2023 | 4y 1mo | — | 7y 3moFeb 2019 - now |
2019 pullback2019 | -9.26%Feb 2019 | 2d | 12d | 14dFeb 2019 - Feb 2019 |
2019 pullback2019 | -1.86%Jan 2019 | 0s | 6d | 6dJan 2019 - Jan 2019 |
2019 pullback2019 | -0.20%Jan 2019 | 0s | 1d | 1dJan 2019 - Jan 2019 |
Drawdown Indicators
| CRDL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.71% | -56.78% | -35.93% |
Max Drawdown (1Y)Largest decline over 1 year | -39.87% | -9.10% | -30.77% |
Max Drawdown (3Y)Largest decline over 3 years | -72.73% | -18.90% | -53.83% |
Max Drawdown (5Y)Largest decline over 5 years | -90.72% | -25.43% | -65.29% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -81.91% | -0.74% | -81.17% |
Average DrawdownAverage peak-to-trough decline | -68.97% | -10.72% | -58.25% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.03% | 1.97% | +25.06% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cardiol Therapeutics Inc Class A over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cardiol Therapeutics Inc Class A is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CRDL in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, CRDL has a P/B value of 6.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CRDL
Add Cardiol Therapeutics Inc Class A to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CRDL